ArticleTranslational andrology and urology2025
Improvements in the prognosis of patients with stage IV renal cancer according to the era of therapeutic agents: an analysis of National Cancer Registry data.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Advances in new drugs have been associated with improvements in the prognoses of individuals with stage IV renal carcinoma. We aimed to retrospectively evaluate the prognostic improvement of stage IV renal cancer over time using the Okayama Cancer Registry database, which is included in the National Cancer Registry (NCR) of Japan. Methods: Patients identified in the database with stage IV renal cancer were included. Survival prognosis was analyzed by three periods according to significant advancements in novel therapeutic agents: early (up to March 2008), mid (April 2008-July 2016), and late (August 2016 onward). Overall survival (OS) was analyzed using the Kaplan-Meier methods and Cox proportional hazards models. Stratified Cox models were used to account for proportional hazards violations. Subgroup analyses included stratification by surgery status and disease extent (T4 Results: In total, 1,182 patients were included in the study. The OS outcomes significantly improved across each period [early: reference; mid: hazard ratio (HR) =0.68, 95% confidence interval (CI): 0.59-0.78; late: HR =0.54, 95% CI: 0.41-0.69]. Subgroup analyses revealed that patients who had undergone initial surgery showed improved prognosis (early: reference; mid: HR =0.44, 95% CI: 0.29-0.69; late: HR =0.30, 95% CI: 0.16-0.56), whereas those receiving no initial surgery did not (early: no case available; mid: reference; late: HR =0.99, 95% CI: 0.64-1.53). Stratified Cox analysis identified age ≥70 years (HR =1.69, 95% CI: 1.47-1.95) and M1 disease (HR =2.95, 95% CI: 2.47-3.52) as independent predictors of worse survival. Significant improvement over time was observed among patients with T4 disease (early: reference; mid: HR =0.59, 95% CI: 0.42-0.82; late: HR =0.47, 95% CI: 0.27-0.81), patients, whereas no improvement was seen in those with M1 disease. Conclusions: Prognosis of patients with stage IV renal cancer has improved over time, particularly among patients with locally advanced disease and those who undergo surgery. Therefore, therapeutic advances may have greater real-world impact on patients with resectable disease than on those with metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.